Table 1.
Treatment groups
| n | Number of tumors implanted | Treatment group | Dose (mg/kg) | Route of administration | Treatment days |
|---|---|---|---|---|---|
| 6 | 1 | untreated | – | – | – |
| 10 | 1 | vehiclea | – | ITb | 1, 8, 15 |
| 10 | 1 | docetaxel | 10 and 5 | IV | 1, 11 |
| 10 | 1 | NanoDoce-1 | 27.5 | IT/PTc | 1, 8, 15 |
| 10 | 1 | NanoDoce-1 | 27.5 | IT | 1, 8, 15 |
| 10 | 1 | NanoDoce-2 | 55 | IT/PT | 1, 8, 15 |
| 10 | 1 | NanoDoce-2 | 55 | IT | 1, 8, 15 |
| 15 | 2 | vehicle-2° | – | IT | 1, 8, 15 |
| 15 | 2 | docetaxel-2° | 10 and 5 | IV | 1,11 |
| 15 | 2 | NanoDoce-1-2° | 27.5 | IT/PT | 1, 8, 15 |
aVehicle formulation = 0.22% polysorbate 80/1.76% ethanol in saline; bIntratumoral (IT) administration; cIntratumoral/peritumoral (IT/PT) administration